All In Biotech

Investigational drug · Phase 3

Bomedemstat

Also called: MK-3543, IMG-7289

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

4 still active

All registered trials

17

Any phase or sponsor naming "Bomedemstat"

First trial start

2023

Sep 7, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Bomedemstat", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Polycythemia Vera
  • Essential Thrombocythemia
  • Thrombocythemia, Essential
  • Primary Myelofibrosis
  • Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis

Approved drugs for the same conditions: Myelofibrosis · Hematology and blood cancers · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "Bomedemstat" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 30 on PubMed

Also in development for Polycythemia Vera

  • KRT-232NavtemadlinPhase 34 trials

    Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

  • SapablursenISIS 702843, ONO-0530Phase 32 trials

    Ono Pharmaceutical Co., Ltd. · Polycythemia Vera, Phlebotomy Dependent Polycythemia Vera

  • AG-236Phase 31 trial

    Agios Pharmaceuticals, Inc. · Polycythemia Vera

  • JBI-802Phase 21 trial

    Jubilant Therapeutics Inc. · Essential Thrombocythemia (ET), Polycythemia Vera

  • SLN124Phase 21 trial

    Silence Therapeutics plc · Polycythemia Vera

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.